China Rolls Out 2026–2030 Eye Health Work Plan – Targeting Cataract Surgery Rate Above 4,000 Per Million and County‑Level Service Coverage by 2030

Beijing, China – Sep 2026 – The National Health Commission (NHC), the National Administration of Traditional Chinese Medicine (NATCM) and the National Disease Prevention and Control Administration (NDCP) have jointly issued the “Work Plan for Accelerating the Provision of High‑Quality and Efficient Eye Health Services (2026–2030)” (Guo Wei Yi Zheng Fa [2026] No. 22), a five‑year blueprint that shifts eye care from a disease‑treatment center to a health center, anchored by hard 2030 targets on cataract surgery rates, ophthalmologist density, and county‑level service capability.

Policy Milestone

ItemDetail
Issuing AuthoritiesNHC, NATCM, NDCP (joint)
DocumentWork Plan for Accelerating High‑Quality and Efficient Eye Health Services (2026–2030)
Document No.Guo Wei Yi Zheng Fa [2026] No. 22
Policy Period2026–2030 (“15th Five‑Year Plan” window)
Issuance DateAnnounced recently; exact date not disclosed in the interpretation
Guiding ApproachPrevention first, medical‑prevention integration, equal emphasis on TCM and Western medicine, multi‑disease co‑prevention and co‑management
Service ChainFull‑chain prevention–screening–diagnosis–treatment–rehabilitation, covering the entire life cycle

2030 Targets

IndicatorTarget by 2030
Refractive ScreeningSteadily rising screening rates for children aged 0–6 and primary/secondary students; stronger correction awareness among the elderly; sustained high effective refractive‑error correction coverage
Cataract Surgery Rate (CSR)>4,000 per million population; effective cataract surgery coverage continuously rising
Workforce>5.3 practicing (assistant) ophthalmologists per 100,000 population; expanded optometrist ranks
County Capability>93% of county general hospitals with an ophthalmology (ENT‑ophthalmology) department; >95% of counties independently diagnosing and treating common eye diseases; 100% of counties able to deliver cataract surgery

Nine Task Areas

  • Risk Prevention: Control modifiable risk factors to lower eye‑disease incidence.
  • Service System: Implement functional positioning of institutions and refine the prevention‑treatment service network.
  • Early Detection: Strengthen early screening for eye diseases.
  • Clinical Standards: Normalize diagnosis and treatment and lift overall service quality.
  • Rehabilitation: Improve low‑vision rehabilitation and ophthalmic rehab capacity.
  • Key Disease Management: Scientific correction of refractive errors, consolidation of cataract blindness‑elimination gains, optimized service models for diabetic retinopathy and other fundus diseases and glaucoma, and stronger prevention of other eye conditions.
  • TCM Synergy: Leverage Traditional Chinese Medicine advantages and promote integrated Chinese–Western care.
  • Digital & AI: Use information technology to empower eye health services with artificial intelligence.
  • Talent & Science: Strengthen workforce training and scientific‑technological support.

Implementation Structure

  • Lead: Health‑administration departments at all levels coordinate rollout and whole‑population, whole‑life‑cycle service management.
  • TCM Departments: Promote ophthalmic TCM‑appropriate technologies and featured therapies; drive integrated prevention and treatment.
  • Disease‑Control Departments: Conduct routine surveillance and intervention on myopia and other common student diseases and their risk factors.
  • Provincial Execution: Provincial health authorities tailor supporting measures to local conditions and establish monitoring and evaluation mechanisms to ensure tasks land in detail.

Market Impact & Outlook

  • Volume Tailwind for Ophthalmology Services: A CSR push above 4,000 per million — from an already substantial base — plus mandated county‑level cataract surgery capability signals sustained growth in surgical volumes, IOL implants, and ophthalmic equipment demand through 2030.
  • Screening Economy: Rising refractive‑screening coverage for children and students institutionalizes a recurring, population‑scale screening funnel, benefiting optical chains, myopia‑control products, and vision‑care providers nationwide.
  • Workforce Expansion as Capacity Unlock: The 5.3‑per‑100,000 ophthalmologist floor and optometrist build‑out address the sector’s core bottleneck, easing constraints on both public hospital eye departments and private expansion.
  • AI Integration Mandate: Explicit endorsement of AI empowerment opens deployment pathways for AI‑assisted fundus screening and diagnostics — a category already piloted in China’s primary‑care network — with county‑level screening needs as the natural first market.
  • Policy Continuity: Building on programs dating to the 1980s and “14th Five‑Year” gains, the plan’s multi‑department, monitored implementation framework makes target slippage visible — and sector budgeting more predictable.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding implementation timelines, service‑coverage targets, workforce expansion, and technology adoption under China’s 2026–2030 Eye Health Work Plan. Actual outcomes may differ due to risks including provincial execution capacity, funding allocation, workforce training pipelines, and evolving clinical‑technology standards.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/yzygj/c100067/202609/13cb984a2d2f4c4383d97b78c3a2b7ea.shtml

China’s CDE Opens Public Consultation on the 110th Batch Catalogue of Reference Preparations for Chemical Generic Drugs – Comment Window Runs 7–18 Sep 2026

Beijing, China – 07 Sep 2026 – The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has published the Catalogue of Reference Preparations for Chemical Generic Drugs (110th Batch) (Draft for Comments) for public consultation, inviting industry feedback through the “Query on Reference Preparation Varieties” module of the official selection application platform until 18 Sep 2026.

Regulatory Milestone

ItemDetail
Issuing AuthorityCenter for Drug Evaluation (CDE), NMPA
DocumentCatalogue of Reference Preparations for Chemical Generic Drugs — 110th Batch (Draft for Comments)
Policy BasisNMPA Announcement No. 25 of 2019 — Procedures for the Selection and Determination of Reference Preparations for Chemical Generic Drugs
Publication Date7 Sep 2026
Comment Period7 Sep – 18 Sep 2026 (10 business days)
Varieties CoveredSee official attachment; count not restated in the notice body
Feedback Channel“Reference Preparation Query Application” module, Reference Preparation Selection Application Platform

Consultation & Feedback Procedure

  • Submission Route: Comments must be filed via the dedicated “query on reference preparation varieties” module on the CDE’s selection application platform — not by mail or email.
  • Evidence Standard: To better serve applicants, the CDE requires feedback to be accompanied by sufficient basis and supporting argumentation materials.
  • Formalities: Submissions must bear the official seal of the organization, together with the submitter’s real name and contact details — anonymous or unsubstantiated comments will not meet the stated requirements.

Reference Preparation Framework

  • Role of Reference Preparations: Designated reference preparations (参比制剂) — typically originator or internationally recognized benchmark products — serve as the comparator standard for bioequivalence studies and quality/therapeutic consistency evaluation of chemical generics in China.
  • Batch Mechanism: The CDE publishes the catalogue in sequential batches under the 2019 selection procedure; each finalized batch gives generic developers a definitive comparator for their generic (ANDA‑equivalent) filings.
  • Draft‑Stage Leverage: The 10‑business‑day comment window is the industry’s formal opportunity to challenge or refine proposed selections — a step that can materially affect development strategy and clinical study design for generics in the covered varieties.

Market Impact & Outlook

  • Pipeline Planning Signal: Generic manufacturers targeting the varieties in the 110th batch should review the draft attachment immediately and calendar the 18 Sep deadline — comparator designation locks in bioequivalence study design and reference‑product sourcing.
  • Consistency Evaluation Momentum: The steady cadence of batch releases (now at 110) underscores the NMPA’s continuing push to align China’s generic fleet with international reference standards, a core plank of procurement eligibility and hospital access.
  • Compliance Posture: The CDE’s insistence on sealed, evidenced, named submissions indicates that only well‑documented objections are likely to influence the final catalogue — favoring applicants with regulatory‑affairs depth.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the consultation outcome, final composition of the 110th batch catalogue, and subsequent generic development implications. Actual results may differ due to risks including feedback evaluation, revisions between draft and final versions, and future CDE policy announcements.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/b5a3b0d7d48c754d41577d2536109f0f

Yunnan Publicizes Essential Drug Attribute Changes for 37 Online Trading Products – Notification‑Commitment Filing Launched Immediately

Kunming, China – 07 Sep 2026 – The Yunnan Provincial Government Procurement and Transfer Center has published the changes in drug attributes for online trading, covering 37 product entries realigned with the National Essential Drug List (2026 Edition), and announced that notification‑commitment filing (告知承诺备案) for essential‑drug status takes effect immediately for all listed products attributed as “Essential Drug (including former provincial supplement).”

Procurement Milestone

ItemDetail
Issuing AuthorityYunnan Provincial Government Procurement and Transfer Center
Notice TypePublic disclosure of drug attribute changes (online trading platform)
Policy BasisNational Essential Drug List (2026 Edition)
Scope37 product entries across injectables, inhalation solutions, oral solids, TCM preparations and topical dosage forms
Disclosure Date7 Sep 2026
Key ConstantsApproval numbers unchanged; procurement ceiling prices unchanged for all entries
Filing RequirementNotification‑commitment filing with the Yunnan Provincial Medical Products Administration (MPA) — effective immediately
Objection Window5 business days from the disclosure date

Attribute Changes at a Glance

CategoryEntriesRepresentative ProductsChange
Essential‑drug status retained32Esomeprazole sodium for injection, ambroxol injection, milrinone injection, somatostatin for injection, nintedanib esylate soft capsules, cilostazol tablets, edaravone–dexborneol injection, ipratropium bromide inhalation solution (7 entries), azithromycin dry suspensionEssential drug → Essential drug (2026 List)
Upgraded to essential drug3Dalteparin sodium injection; nadroparin calcium injection (2 specs) — Yantai Dongcheng Northern PharmaceuticalNon‑essential → Essential drug
Reclassified to former provincial supplement2Dengzhanxixin granules — Yunnan Plant PharmaceuticalEssential drug → Former provincial supplement (原省补)
  • Manufacturer Footprint: The batch spans roughly 20 producers, including Langtian Pharmaceutical (Hubei) (9 entries), Simcere Pharmaceutical, Chengdu Beit, Shaanxi Hanwang, and France‑based Laboratoire Unither, whose ipratropium bromide solution is bid through Sinopharm Distribution Center — evidence of continued import participation in Yunnan’s platform.

Essential Drug Filing Obligation

  • Who Must Act: All enterprises whose products carry the “Essential Drug (including former provincial supplement)” attribute in the disclosure.
  • Procedure: Complete the notification‑commitment filing per the Yunnan Provincial MPA’s published requirements, bringing a printed copy of this announcement to the designated filing site.
  • Filing Site: Reception Hall, 1st Floor, Yunnan Institute for Food and Drug Control (new building, 616 Kefa Road, Kunming); filing hotline 0871‑63112057.
  • Compliance Warning: Enterprises that fail to complete the filing bear the consequences — a clear signal that unfiled products risk losing essential‑drug procurement privileges on the platform.

Objection & Public Supervision

  • Applicant Enterprises: Queries on the disclosed information must be raised within 5 business days to the Center’s Drug & Device Procurement Section (0871‑63606934).
  • General Public & Third Parties: Objections to the disclosure are accepted within 5 business days by the Comprehensive Supervision Section (0871‑65330065), keeping the process open to public scrutiny.

Market Impact & Outlook

  • 2026 List Alignment: This batch operationalizes the National Essential Drug List (2026 Edition) at the provincial trading level, with price ceilings and approval numbers held steady — suppliers gain attribute certainty without repricing risk.
  • Anticoagulant Upgrade: The promotion of dalteparin and nadroparin from non‑essential to essential status strengthens the procurement position of Yantai Dongcheng Northern Pharmaceutical in Yunnan’s public‑hospital channel.
  • TCM Reclassification: Moving dengzhanxixin granules to the “former provincial supplement” track preserves preferential treatment for legacy provincial items even after national‑list streamlining.
  • Filing as Gatekeeper: The immediate‑effect notification‑commitment regime makes filing a de facto compliance checkpoint — enterprises should treat it as a short‑fuse administrative deadline tied directly to continued listing.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding filing completion, objection outcomes, and procurement treatment of the disclosed products. Actual results may differ due to risks including filing verification, third‑party objections, and subsequent announcements by the Yunnan Provincial MPA and the Center.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27813&CatalogId=3